Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FUJIFILM's Q1 revenue hit a record yen 826.5 billion, but earnings fell 30% as Bio CDMO costs and restructuring weighed on profitability.
FUJIY posted record Q4 revenue and profit as healthcare, semiconductor materials and imaging demand lifted results and fueled upbeat FY2026 outlook.
| Health Care Equipment & Supplies Industry | Healthcare Sector | Teiichi Goto CEO | XFRA Exchange | 35958N107 CUSIP |
| JP Country | 73,526 Employees | 29 Sep 2026 Last Dividend | 2 Apr 2024 Last Split | - IPO Date |
FUJIFILM Holdings Corporation, established in 1934 and based in Tokyo, Japan, stands as a global developer, manufacturer, seller, and service provider of innovative solutions across Imaging, Healthcare, Materials, and Business Innovation domains. The corporation caters to a wide array of sectors by providing distinctive products and services aimed at the prevention, diagnosis, and treatment in healthcare; advancing printing and industrial materials; enhancing office environments through business innovation solutions; and enriching the imaging culture with high-quality products. FUJIFILM's commitment to innovation and sustainability is evident in its diverse portfolio, catering to the evolving needs of businesses and consumers worldwide.
Healthcare Segment:
Materials Segment:
Business Innovation Segment:
Imaging Segment: